Reshape Lifesciences Inc. Stock Price, News & Analysis

ReShape Lifesciences (Nasdaq: RSLS) has received a Notice of Allowance from the USPTO for patent application 18/241,151, titled 'Intragastric Device.' The patent covers an innovative intragastric balloon system featuring a swallowable capsule with self-sealing fill valve and degradable release valve.

The system is designed to deflate approximately three months after saline inflation and is configured for natural excretion. The patent will provide protection until at least January 2031, with potential for extension.

Since their initial filing in 2011, the company has secured over 50 patents related to their intragastric balloon system. ReShape currently maintains a portfolio of more than 160 patents issued and pending across various protected technologies.

ReShape Lifesciences (RSLS) has received a USPTO Notice of Allowance for patent application 18/069,689, titled 'High-Frequency Low Duty Cycle Patterns for Neural Regulation', providing protection until August 2037. The patent covers their Diabetes Neuromodulation system which utilizes proprietary vBloc™ technology for treating Type 2 diabetes through vagal nerve modulation.

The technology features an energy-efficient algorithm that uses discontinuous high-frequency signals with interwoven micro- and millisecond pauses, consuming 10 times less energy than traditional continuous signals. Preclinical testing on rat vagus nerves has shown equivalent efficacy while remaining compatible with standard implantable pulse generators.

The company's intellectual property portfolio includes 63 issued or pending patents covering vagal neuromodulation, glucose regulation, artificial intelligence, and Bluetooth-enabled applications.

ReShape Lifesciences (RSLS) has entered an exclusive U.S. distribution agreement with Motion Informatics to import and distribute neuromuscular rehabilitation devices. The partnership's flagship product is the FDA-cleared Stimel-03, which combines Functional Electrical Stimulation, Neuromuscular Electrical Stimulation, and real-time EMG biofeedback in a single platform.

The system is designed for patients recovering from stroke, injury, or surgery, and can be used in both clinical and home settings. Motion Informatics is also developing Spatial StimelMD (SSMD), a next-generation platform that incorporates AI-personalized neuromodulation, EMG biofeedback, and augmented reality for adaptive rehabilitation.

ReShape Lifesciences (NASDAQ: RSLS) reported its financial results for the year ended December 31, 2024, highlighting a significant 41.9% reduction in operating expenses compared to 2023. The company's revenue totaled $8.0 million, showing a 7.7% decrease from 2023, primarily due to GLP-1 pharmaceuticals impact.

Key financial metrics include: gross profit of $5.1 million (63.2% margin), decreased sales and marketing expenses by 60.4% to $3.0 million, reduced general and administrative expenses by 32.9% to $6.9 million, and R&D expenses down 22.1% to $1.8 million.

The company announced a pending merger with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys. Additionally, ReShape secured new patents for its Diabetes Neuromodulation system, signed a Canadian distribution agreement for Lap-Band 2.0 FLEX, and completed a $6.0 million public offering in February 2025.

ReShape Lifesciences (RSLS) has received a Notice of Allowance from the USPTO for patent application 17/046,677, focused on their Diabetes Neuromodulation technology. The patent, valid until April 2039, covers 'Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic Control System and Methods.'

The technology combines vagus nerve block (vBloc™) with vagus nerve stimulation to treat Type 2 diabetes. It aims to reduce medication dependence through personalized glucose control. The system is backed by a robust IP portfolio of 62 issued or pending patents covering vagal neuromodulation, glucose control, AI, and Bluetooth applications.

Pre-clinical development has shown promising results in both Zucker rat and alloxan-treated swine models of Type 2 Diabetes Mellitus (T2DM). The technology works by selectively modulating vagal block and stimulation to the liver and pancreas, potentially offering treatment for both Type 2 diabetes and hypoglycemia.

ReShape Lifesciences (Nasdaq: RSLS) has signed a distribution agreement with Liaison Medical for its next-generation Lap-Band® 2.0 FLEX in Canada, following Health Canada's approval in November 2024. This enhanced weight loss device features innovative FLEX technology that acts as a relief valve when patients swallow large food pieces, potentially eliminating the need for in-office band adjustments.

Paul F. Hickey, ReShape's CEO, noted that initial surgeon feedback from the U.S. market release has been "overwhelmingly positive." Denis Langevin, CEO of Liaison Medical, expressed excitement about the partnership, highlighting his company's position as one of Canada's largest surgical device distributors with established relationships with bariatric surgeons. Langevin believes the improved features of the Lap-Band® 2.0 FLEX will serve as a "growth catalyst" for ReShape Lifesciences.

ReShape Lifesciences (Nasdaq: RSLS) has announced the pricing of an upsized $6.0 million public offering consisting of 2,575,107 units at $2.33 per unit. Each unit includes one common share (or pre-funded warrant) and one warrant to purchase one common share. The warrants will be exercisable at $5.83 per share after stockholder approval, with a one-time reset option and alternative cashless exercise provision.

The warrants will expire either 12 days after stockholder approval or within 60 days after approval, coinciding with the company's planned merger with Vyome Therapeutics. The offering is expected to close around February 18, 2025, with Maxim Group serving as the sole placement agent.

ReShape Lifesciences (RSLS) has been granted Patent Number 277949 in Israel for its Diabetes Neuromodulation technology, providing protection until December 4, 2039. The technology combines the company's proprietary vagus nerve block (vBloc™) platform with vagus nerve stimulation to treat Type 2 diabetes.

The system aims to reduce diabetics' medication dependence through personalized treatment, potentially lowering costs and complications associated with poor blood glucose control. The technology is supported by a strong intellectual property portfolio of 62 issued or pending patents related to vagal neuromodulation, glucose control, AI, and Bluetooth applications.

Pre-clinical development has been completed, demonstrating increased glycemic control in both Zucker rat and alloxan treated swine models of Type 2 Diabetes Mellitus (T2DM). The technology works by selectively modulating vagal block and stimulation to the liver and pancreas.

ReShape Lifesciences (Nasdaq: RSLS) provided updates on its merger agreement with Vyome Therapeutics and asset purchase agreement with Biorad Medisys. The all-stock merger will create a combined company renamed to Vyome Holdings, trading under ticker 'HIND'. The new board will include six Vyome-designated directors and one ReShape director.

Through the asset purchase agreement, Biorad will acquire substantially all of ReShape's assets, including the Lap-Band System, Obalon Gastric Balloon System, and DBSN System, assuming all related liabilities. The cash purchase price will count toward ReShape's net cash for post-merger ownership allocation.

ReShape filed an S-4 registration statement for the merger on October 1, 2024, with an amendment on December 6, and a Form S-1 registration statement for an Equity Line of Credit with Ascent Partners Fund on December 20. The combined company will focus on Vyome's immuno-inflammatory assets and opportunities between the U.S.-India innovation corridor.